• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性冠状动脉综合征患者中凝血因子VIII和血管性血友病因子(vWF)水平升高与SYNTAX评分的相关性

The Association of Elevated Factor VIII and von Willebrand Factor (vWF) Levels with SYNTAX Score in Patients with Chronic Coronary Syndrome.

作者信息

Djuric Predrag, Mladenovic Zorica, Jovic Zoran, Vukotic Snjezana, Spasic Marijan, Mijuskovic Mirjana, Terzic Brankica, Radojicic Zoran, Radisavljevic Nina, Djuric Marko, Djuric Dragan

机构信息

Clinic for Cardiology, Military Medical Academy, 11040 Belgrade, Serbia.

Clinic for Urgent Internal Medicine, Military Medical Academy, 11040 Belgrade, Serbia.

出版信息

Biomedicines. 2025 Sep 17;13(9):2284. doi: 10.3390/biomedicines13092284.

DOI:10.3390/biomedicines13092284
PMID:41007843
Abstract

Factor VIII (FVIII) and the von Willebrand factor (vWF) are key components of hemostatic balance. Disruption of the vWF-ADAMTS13 axis, characterized by elevated vWF and reduced ADAMTS13 activity has been implicated in thrombotic disorders, including COVID-19-asscoiated coagulopathy, where this imbalance correlates with disease severity and mortality. This study evaluated the relationship between plasma FVIII and vWF levels and the severity of coronary artery disease (CAD), as assessed by the SYNTAX score. We enrolled 82 patients with chronic coronary syndrome (CCS) and a positive treadmill test who underwent elective coronary angiography. Based on the SYNTAX score, patients were divided into three groups: Group I (≤22), Group II (23-32), and Group III (≥33). FVIII levels varied significantly (Group I: 2.25 ± 0.75; Group III: 2.97 ± 0.95; = 0.007), with an OR of 3.632 (95% CI: 1.116-11.826; = 0.03). vWF levels differed significantly across SYNTAX groups (Group I: 1.16 ± 0.59; Group II: 1.52 ± 0.62; Group III: 1.49 ± 0.80; = 0.040). vWF > 1.75 was more frequent in Groups II and III, with an odds ratio (OR) of 4.909 (95% CI: 1.429-16.864; = 0.01) for Group III vs. Group I. Fibrinogen and C-reactive protein (CRP) were elevated in patients with SYNTAX scores ≥33. In multinomial logistic regression analysis, FVIII emerged as the sole independent predictor of CAD complexity ( = 0.004), while the vWF showed significance in pairwise comparison (Group II vs. Group I; OR = 3.433, = 0.049). This study demonstrated significant differences in hemostatic and inflammatory biomarkers across SYNTAX score categories reflecting CAD severity in CCS patients. FVIII emerged as an independent predictor of CAD complexity, while the vWF demonstrated significant associations in specific subgroup comparisons. The observed vWF-ADAMTS13 axis dysregulation supports the rationale for investigating vWF-targeted therapeutics, including agents such as caplacizumab, in cardiovascular disease management. These findings require validation in larger studies.

摘要

凝血因子VIII(FVIII)和血管性血友病因子(vWF)是止血平衡的关键组成部分。以vWF升高和ADAMTS13活性降低为特征的vWF-ADAMTS13轴破坏与血栓形成性疾病有关,包括与COVID-19相关的凝血病,这种失衡与疾病严重程度和死亡率相关。本研究评估了血浆FVIII和vWF水平与冠状动脉疾病(CAD)严重程度之间的关系,CAD严重程度通过SYNTAX评分进行评估。我们纳入了82例慢性冠状动脉综合征(CCS)且平板运动试验阳性并接受选择性冠状动脉造影的患者。根据SYNTAX评分,患者分为三组:I组(≤22分)、II组(23 - 32分)和III组(≥33分)。FVIII水平差异显著(I组:2.25±0.75;III组:2.97±0.95;P = 0.007),比值比为3.632(95%置信区间:1.116 - 11.826;P = 0.03)。vWF水平在不同SYNTAX组间存在显著差异(I组:1.16±0.59;II组:1.52±0.62;III组:1.49±0.80;P = 0.040)。II组和III组中vWF>1.75更为常见,III组与I组相比比值比(OR)为4.909(95%置信区间:1.429 - 16.864;P = 0.01)。SYNTAX评分≥33的患者纤维蛋白原和C反应蛋白(CRP)升高。在多项逻辑回归分析中,FVIII成为CAD复杂性的唯一独立预测因子(P = 0.004),而vWF在两两比较中具有显著性(II组与I组比较;OR = 3.433,P = 0.049)。本研究表明,在反映CCS患者CAD严重程度的不同SYNTAX评分类别中,止血和炎症生物标志物存在显著差异。FVIII成为CAD复杂性的独立预测因子,而vWF在特定亚组比较中显示出显著关联。观察到的vWF-ADAMTS13轴失调支持了在心血管疾病管理中研究以vWF为靶点的治疗方法的理论依据,包括诸如卡帕单抗等药物。这些发现需要在更大规模的研究中进行验证。

相似文献

1
The Association of Elevated Factor VIII and von Willebrand Factor (vWF) Levels with SYNTAX Score in Patients with Chronic Coronary Syndrome.慢性冠状动脉综合征患者中凝血因子VIII和血管性血友病因子(vWF)水平升高与SYNTAX评分的相关性
Biomedicines. 2025 Sep 17;13(9):2284. doi: 10.3390/biomedicines13092284.
2
Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis.COVID-19 患者血管性血友病因子和 ADAMTS13 的预后价值:系统评价和荟萃分析。
Thromb Res. 2022 Oct;218:83-98. doi: 10.1016/j.thromres.2022.08.017. Epub 2022 Aug 18.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study.新型冠状病毒肺炎凝血病是血栓性微血管病吗?一项前瞻性观察性研究。
Int J Mol Sci. 2025 Jun 4;26(11):5395. doi: 10.3390/ijms26115395.
5
Vesicoureteral Reflux膀胱输尿管反流
6
Determining the Impact of Combination Oral Contraceptives on Von Willebrand Factor and Factor VIII in Healthy Patients and Patients With Von Willebrand Disease: A Scoping Review and Meta-Analysis.确定复方口服避孕药对健康患者及血管性血友病患者血管性血友病因子和凝血因子VIII的影响:一项范围综述和荟萃分析。
Haemophilia. 2025 Sep 11. doi: 10.1111/hae.70124.
7
Shoulder Arthrogram肩关节造影
8
VON WILLEBRAND FACTOR IN ECMO: A DYNAMIC MODULATOR OF HEMORRHAGE AND THROMBOSIS.体外膜肺氧合中的血管性血友病因子:出血和血栓形成的动态调节因子
Shock. 2025 Sep 1;64(3):291-302. doi: 10.1097/SHK.0000000000002632. Epub 2025 May 16.
9
High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis.COVID-19 中高水平的血管性血友病因子标志物:一项系统评价和荟萃分析。
Clin Exp Med. 2022 Aug;22(3):347-357. doi: 10.1007/s10238-021-00769-x. Epub 2021 Nov 6.
10
Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.凝血因子VIII/蛋白C比值可独立预测与肝脏相关的事件,但在非酒精性脂肪性肝病(ACLD)中并不表明存在高凝状态。
J Hepatol. 2022 May;76(5):1090-1099. doi: 10.1016/j.jhep.2021.12.038. Epub 2022 Jan 20.

本文引用的文献

1
Evaluating caplacizumab's potential to mitigate thrombosis risk in aortic valve stenosis: a microfluidic and computational approach.评估卡帕西珠单抗降低主动脉瓣狭窄血栓形成风险的潜力:一种微流控和计算方法。
Lab Chip. 2025 Aug 8. doi: 10.1039/d5lc00361j.
2
Constitutive interaction between neutrophils and von Willebrand factor in peripheral blood.外周血中中性粒细胞与血管性血友病因子之间的组成性相互作用。
Sci Rep. 2025 Jul 10;15(1):24895. doi: 10.1038/s41598-025-10321-6.
3
High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?
动脉粥样硬化性心血管疾病中的高敏C反应蛋白:测还是不测?
US Cardiol. 2025 Mar 21;19:e06. doi: 10.15420/usc.2024.25. eCollection 2025.
4
Coronary Microvascular Dysfunction: Insights on Prognosis and Future Perspectives.冠状动脉微血管功能障碍:对预后的见解及未来展望
Rev Cardiovasc Med. 2025 Jan 20;26(1):25757. doi: 10.31083/RCM25757. eCollection 2025 Jan.
5
Factor VIII as a Novel Biomarker for Diagnosis, Prognosis, and Therapy Prediction in Human Cancer and Other Disorders.凝血因子VIII作为人类癌症及其他疾病诊断、预后和治疗预测的新型生物标志物。
Avicenna J Med Biotechnol. 2024 Apr-Jun;16(2):68-80. doi: 10.18502/ajmb.v16i2.14857.
6
Acute myocardial infarction in von Willebrand disease: characteristics and outcomes.血管性血友病因子病中的急性心肌梗死:特征与结局
Res Pract Thromb Haemost. 2023 Sep 9;7(7):102198. doi: 10.1016/j.rpth.2023.102198. eCollection 2023 Oct.
7
Von Willebrand factor in diagnostics and treatment of cardiovascular disease: Recent advances and prospects.血管性血友病因子在心血管疾病诊断与治疗中的应用:最新进展与展望
Front Cardiovasc Med. 2022 Dec 2;9:1038030. doi: 10.3389/fcvm.2022.1038030. eCollection 2022.
8
Regulation of VWF (Von Willebrand Factor) in Inflammatory Thrombosis.炎症性血栓形成中 vWF(血管性血友病因子)的调节。
Arterioscler Thromb Vasc Biol. 2022 Nov;42(11):1307-1320. doi: 10.1161/ATVBAHA.122.318179. Epub 2022 Sep 29.
9
Blood fibrinogen level as a biomarker of adverse outcomes in patients with coronary artery disease: A systematic review and meta-analysis.血纤维蛋白原水平作为冠心病患者不良结局的生物标志物:系统评价和荟萃分析。
Medicine (Baltimore). 2022 Aug 19;101(33):e30117. doi: 10.1097/MD.0000000000030117.
10
The Cardioprotective Potential of von Willebrand Disease in Ischemic Heart Disease.血管性血友病在缺血性心脏病中的心脏保护潜力。
Tex Heart Inst J. 2022 Jul 1;49(4). doi: 10.14503/THIJ-20-7402.